CTRC commences enrollment in Phase 2 trial of REOLYSIN combination for SCC lung cancer

CTRC commences enrollment in Phase 2 trial of REOLYSIN combination for SCC lung cancer
A virus that destroys cancer cells but leaves normal cells unharmed may offer hope to those affected by squamous cell carcinoma of the lungs (SCC lung cancer), according to investigators from the Cancer Therapy & Research Center (CTRC) at the University of Texas Health Science Center at San Antonio. The CTRC has started patient enrollment in a US Phase 2 clinical trial using intravenous …

Read more on News-Medical-Net

Related posts

DC-SCRIPT Found to Have Prognostic Value in Breast Cancer

In this study, a team led by Gosse J. Adema, Ph.D., of the Department of Tumor Immunology, at the Radboud University Nijmegen Medical Centre, the Netherlands, and colleagues assessed the role of DC-SCRIPT as a co-regulator of nuclear receptors, including estrogen receptor (ER), progesterone receptor (PR)-B, peroxisome proliferator-activated receptor gamma, and retinoic acid receptor alpha. Prognostic value was assessed in three independent cohorts of breast cancer patients.

The researchers found that DC-SCRIPT suppressed ER- and PR-mediated transcription in a ligand-dependent fashion, whereas it enhanced the activity of the other two receptors. Quantification of DC-SCRIPT mRNA expression in the three cohorts of patients revealed that this expression is an independent prognostic factor for breast cancer patients with ER- and/or PR-positive tumors, according to the authors.

» Read more: DC-SCRIPT Found to Have Prognostic Value in Breast Cancer

Related posts

WATCH: FDA Considers New Cancer Vaccine

WATCH: FDA Considers New Cancer Vaccine
Dr. Richard Besser discusses the possible approval of a prostate cancer vaccine. Cancer – Food and Drug Administration – Health – Conditions and Diseases – Genitourinary

Read more on ABC News

Related posts